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Abstract 
Objectives  
Health interventions for patients can have effects on their carers too.  For consistency, decision-
makers may wish to specify whether carer outcomes should be included. One example is the 
National Institute for Health and Care Excellence (NICE), whose Reference Case specifies that 
economic evaluations should include direct health effects for patients and carers where 
relevant. We aimed to review the methods used in including carer health-related quality of life 
(HRQL) in NICE appraisals. 
Methods 
We reviewed all published Technology Appraisals (TAs) and Highly Specialised Technologies 
(HSTs) to identify those that included carer HRQL, and discussed the methods and data 
sources. 
Results 
Twelve of 414 TAs (3%) and four of eight HSTs (50%) included carer HRQL in cost-utility 
analyses. Eight were for multiple sclerosis, the remainder were each in a unique disease area. 
Twelve of the 16 appraisals modelled carer HRQL as a function of the patient’s health state, 
three modelled carer HRQL as a function of the patient’s treatment and one included family 
quality-adjusted life year (QALY) loss. They used five source studies: two compared carer EQ-
5D scores with controls, two measured carer utility only (one HUI and one EQ-5D), and one 
estimated family QALY loss from a child’s death. Two used disutility estimates not from 
literature. Including carer HRQL increased the incremental QALYs and decreased incremental 




The inclusion of carer HRQL in NICE appraisals is relatively uncommon and has been limited 
by data availability.  
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Highlights 
● NICE states that economic evaluations should include direct health effects for all 
individuals, including carers where relevant, yet the inclusion of carer health outcomes 
in NICE technology appraisals and highly specialised technologies is relatively 
uncommon. 
● The studies used to estimate carer health outcomes in NICE appraisals used various 
utility measures, some used non-UK populations, some were from other disease areas 
or populations, and some required comparison to general population utilities.  
● In the absence of clear guidance from health technology assessment bodies such as 
NICE, inclusion of carer health outcomes will be inconsistent between appraisals. 
  
Body of article 
Introduction 
Health interventions for patients can affect outcomes for informal carers too. For example, an 
intervention may reduce the amount of informal care required and so improve the quality of 
life of the informal carer[1]. Conversely, an increased requirement for care may entitle the 
patient to formal (paid) care, which may alleviate the burden on informal carers. Furthermore, 
a patient’s health may directly influence the wellbeing of others who care about them as well 
as those who care for them[2]. Economic evaluations of health interventions have traditionally 
focused on outcomes for the patient, but a small proportion of studies have also included 
outcomes for carers[3, 4]. Ignoring the potentially large impacts to carers may be inequitable 
and inefficient[5]. 
Variation in how costs and outcomes are included will cause inconsistency in comparing 
between different economic evaluations. Health Technology Assessment (HTA) agencies may 
therefore produce a “Reference Case”, specifying the methods that should be used. One 
example of this is the Reference Case for Technology Appraisals produced by the National 
Institute for Health and Care Excellence (NICE) in England[6]. NICE’s Reference Case 
stipulates that cost-utility analyses should be used, with costs relating to those under the control 
of the National Health Service and personal social services and outcomes measured in quality-
adjusted life years (QALYs). Outcomes should be direct health effects, whether for patients or, 
when relevant, carers. The EQ-5D is NICE’s preferred measure of health-related quality of life 
(HRQL) in adults, and changes in HRQL should be valued using a representative sample of 
the UK population. The Reference Case does not specify how carer HRQL should be included 
in cost-utility analyses, or how the relevance of health effects for carers should be 
determined[6]. The Second Panel on Cost-Effectiveness in Health and Medicine in the US 
similarly recommend that health effects should be those accruing to patients and other affected 
parties including caregivers[7]. By comparison, Guidelines for submissions to the 
Pharmaceutical Benefits and Advisory Committee in Australia[8] specify that health outcomes 
for carers should only be included in sensitivity analysis and not in the base case, and guidelines 
for the Canadian Agency for Drugs and Technologies in Health do not mention carers[9]. We 
were therefore interested, given NICE’s global role in HTA, in the extent to which carer HRQL 
has been included in NICE appraisals.  
Our aim was to understand how carer HRQL has been considered in the analyses and 
recommendation of NICE Technology Appraisals (TAs) and Highly Specialised Technologies 
(HSTs) (for which the NICE Reference Case also applies). In both the TA and HST process, 
the company submits principal evidence on cost-effectiveness which is critiqued by an 
independent assessment group and then discussed by the committee. There may then be further 
evidence submitted by the company and further critique by the assessment group before the 
committee make their final recommendation in the Final Appraisal Determination (FAD) for 
TAs or Final Evaluation Document (FED) for HSTs. The FAD/FED reports the committee 
discussion in developing recommendations and reviewing the cost-effectiveness evidence, so 
reviewing NICE appraisals provides an opportunity to understand not only how analysts have 
included carer HRQL in economic evaluation, but also how independent review groups have 
viewed it and how decision makers have considered carer HRQL in reimbursement decisions.   
 
Our objectives were to review: 
1. Which appraisals and clinical areas have included carer HRQL (in addition to patient 
HRQL) 
2. How carer HRQL has been included in cost-utility analyses  
3. Which sources of evidence have been used to report carer HRQL 
4. How the inclusion of carer HRQL affects incremental QALYs and incremental cost-
effectiveness ratios (ICERs) 
5. Whether NICE committees considered that the inclusion of carer HRQL was relevant 
and appropriate in decision-making 
 
Methods 
On 11 January 2019, we searched for the terms “carer” and “caregiver” within the FAD/FED 
for every TA and HST published on the NICE website since inception in 2000. We read the 
FADs/FEDs that included these terms and included appraisals where the committee 
specifically discussed carer HRQL and its impact on QALYs or ICERs. We excluded 
appraisals that mentioned carers without specifying carer HRQL, for example those that 
acknowledged only that patients with the condition need a carer, or those that discussed there 
are “benefits” or “effects” to carers but without specifying HRQL as these do not clearly fall 
within NICE’s reference case of direct health effects measured in QALYs. We categorised 
included appraisals by those where the cost-utility analysis included carer HRQL in any stage 
of the process, and those where carer HRQL was not included in the cost-utility analysis but 
where the committee did discuss the impact of carer HRQL. 
We reviewed the company submission(s) and independent assessment group report(s) for each 
appraisal and one reviewer extracted data on the clinical area, date of publication, how carer 
HRQL was included in cost-utility analysis, size of carer HRQL impact and number of 
modelled carers, source of carer HRQL data, and the impact of the inclusion of carer HRQL 
on incremental QALYs and ICERs. As there are several stages in which the company and 
independent assessment group may conduct cost-utility analyses and both groups may 
undertake scenario analyses (and in multiple TAs there are several submitting companies), it 
is possible that multiple methods and sources of data could be used to model carer HRQL 
within each appraisal.  We extracted data on each method and data source considered within 
the appraisals. From the FAD/FED, we extracted data on the committee discussion and 
conclusion regarding the inclusion of carer HRQL.  
 
Results 
Of 414 published TAs and eight published HSTs, we identified a total of 73 appraisals where 
the FED/FAD included the term “carer” or “caregiver”. Of these, 12 TAs and four HSTs 
included carer HRQL in the cost-utility analysis. In a further 11 appraisals, the committee 
discussed carer HRQL but it was not included in the cost-utility analysis [see Supplement 1]. 
In the remaining 46 appraisals, the committee discussed carers but not specifically in the 
context of HRQL. A PRISMA flow diagram is provided in Figure 1.  
 
Clinical areas 
The 12 TAs that included carer HRQL in cost-utility analyses were for interventions to treat 
multiple sclerosis (n=8), Alzheimer's disease, juvenile idiopathic arthritis, atopic dermatitis and 
myelofibrosis. The four HSTs were in mucopolysaccharidosis type IVa (MPS IVa), Duchenne 
muscular dystrophy (DMD), adenonsine deaminase deficiency-severe combined 
immunodeficiency (ADA-SCID) and X-linked hypophosphataemia (XLH). The appraisals 
where carer HRQL was discussed but not included in cost-utility analyses were in plaque 
psoriasis in children, juvenile idiopathic arthritis, asthma (n=3), non-small-cell lung cancer, 
cystic fibrosis, alcohol consumption, chronic hepatitis C in children, neuroblastoma and 
paediatric-onset hypophosphatasia. 
 
Of the appraisals that included carer HRQL in the cost-utility analyses, six of the 12 TAs and 
all four HSTs were for either exclusively paediatric populations or combined paediatric and 
adult populations. Furthermore, seven of the 11 appraisals that discussed carer HRQL but did 
not include it in cost-utility analyses included paediatric populations.  
 
How carer HRQL was included in cost-utility analysis 
Table 1 describes how carer HRQL was included in the cost-utility analysis in the TAs and 
HSTs. In each appraisal, the cost-utility analysis used an economic model to simulate patients’ 
experience of a disease with the intervention and comparator. Carers were included by 
modelling carer’s HRQL as a function of either patients’ disease status/health state, patients’ 
treatment or patients’ death. Eleven appraisals used disutilities (utility decrements or losses) 
for carers, modelled as a function of the patient’s health state [10-20]. Three appraisals modelled 
carer HRQL as  function of the treatment the patient received (either as utility increments or 
disutilities), independent of the patient’s health state [21-23]. One appraisal modelled carer 
utilities as a function of patient’s disease severity[24], and one appraisal included a QALY loss 
to the family when the patient died[25]. The size of the carer HRQL impact ranged from an 
increase of 0.01 for a treatment-related increment in the appraisal of atopic dermatitis[23] to a 
disutility of 0.173 in two appraisals in multiple sclerosis[16, 17] and a lifetime QALY loss of 
1.8 to 2.1 in the appraisal that modelled family QALYs as a function of patient death[23]. 
Most of the appraisals included one carer, with the exception of the TA in myelofibrosis which 
included 1.76 carers for 57.48% of patients (based on an unpublished study), the HST in DMD 
which included up to three carers in the company’s analysis[19], and the HST in ADA-SCID 
which did not specify the number of family members[25]. 
Figure 2 reports the number of appraisals that included and excluded carer HRQL over time, 
using different approaches. Since the first TA in 2000, the number of NICE appraisals 
conducted annually has generally increased over time. The first appraisal to include carer 
HRQL was in 2007 (TA127), and the next appraisal to include carer HRQL was not until 2012, 
and since 2014, more appraisals have included carer HRQL.  
  
Source of carer HRQL data 
Five sources provided the estimates of carer HRQL used in the 16 appraisals: Neumann et al 
(2000)[26], Acaster et al (2013)[27], Kuhlthau et al (2010)[28], Landfeldt et al (2014)[29] and 
Christensen et al (2014)[30]. Table 2 reports the country, carer and control population, the 
utility measures and valuation sets used, the outcomes, and which appraisals used the different 
sources. [31-44] 
Acaster et al (2013) generated disutilities as the mean difference between the controls and 
carers, reported by the Patient Determined Disease Steps (PDSS) state[27]. The disutilities 
displayed a non-monotonic pattern, with PDSS 7 and 8 (the most severe states) having smaller 
carer disutilities than PDSS 4-6. The study authors noted this finding and discussed that the 
reasons for it were unclear, with post-hoc analyses suggesting that this was not due to reduced 
burden from external caregiver support. These carer disutilities were used in two multiple 
sclerosis appraisals which modelled patient health using the EDSS, by converting the PDSS 
states from Acaster et al (2013) to the EDSS states in the model[38, 41]. 
Kuhlthau et al (2010)[28] analysed data from the US Medical Expenditure Panel Survey data 
using regression analysis considering multiple variables[40]. This study was used in the 
juvenile idiopathic arthritis TA[40] and in the HST for XLH[42] (although in this case the 
disutility included was 0.08, which is the difference between the mean EQ-5D scores for the 
two groups). 
Landfeldt et al (2014)[29] was used in the HST for DMD, which included a caregiver disutility 
for non-ambulatory patient health states[43, 44]. 
Neumann et al (2000)[26] appears to have been first used to inform carer utilities in TA111 for 
Alzheimer's disease and later used in TA217[31], which superseded TA111 (the FADs for 
superseded appraisals are not published on NICE’s website so were not included in our review). 
The same source was also used in seven multiple sclerosis appraisals, calculating the difference 
between the lowest HUI3 score and full health to give a disutility of 0.14, which was applied 
to the most severe Expanded Disability Status Scale (EDSS) health state[32-38]. A linear 
interpolation was applied to estimate carer disutilities for the remaining health states, with a 
carer disutility of 0 for the state representing no disability. The same source was used in the 
HST for MPS IVa, linking the health states in the multiple sclerosis appraisals with wheelchair 
usage in the model for MPS IVa[39], and in the TA for juvenile idiopathic arthritis[40]. 
Christensen et al (2014) [30] refer to a study by Al-Janabi et al (2015) which reports HRQL 
losses using EQ-5D-5L to the families of meningitis sequalae survivors[45], but note that this 
study did not measure the impact of patient death of family members’ HRQL, so used evidence 
on the impact of bereavement on parent’s HRQL using HUI3[46] and comparison of HRQL 
loss for meningitis sequalae survivors with HRQL loss from death. Numerical calculations are 
not provided. The estimate of 9% was used in the HST for ADA-SCID in a scenario analysis 
to incorporate family QALY loss. 
The Alzheimer's disease TA also considered carer utilities generated from the Short-Form 36 
questionnaire, but no further information was available on this source. The TA for atopic 
dermatitis and the TA for myelofibrosis included increments for carer utility (0.01 and 0.1 for 
atopic dermatitis and 0.1 for myelofibrosis) when patients received treatment[47, 48]. The TA 
for atopic dermatitis refers to a literature review of caregiver disutilities across disease 
areas[49] and the JIA appraisal[21]. The TA for myelofibrosis describes a utility decrement for 
cancer carers of “about -0.10 as measured by the SF-6D” (pp.13 [48]), referenced to a study of 
SF-36 scores which reports a difference of -0.09 between general health scores, measured on 
the 0 to 100 scale[50], and refers to Acaster et al (2013)[27]. Neither TA provided evidence for 
how the treatment itself would improve carer utility.  
 
Impact on incremental QALYs and ICERs 
Information on the impact of including carer HRQL on incremental QALYs and/or on ICERs 
was available for 10 of the appraisals and is presented in Table 3. In the other appraisals, either 
scenarios were not presented or results were confidential. In all cases, including carer HRQL 
increased incremental QALYs and decreased ICERs. Including carer HRQL generally 
increased incremental QALYs by less than 0.03 – although in some cases this represented over 
a 20% increase. Two appraisals (HST3 and HST7) considered scenario analyses where carer 
HRQL had a bigger absolute impact on incremental QALYs, but these were for HSTs with 
high incremental QALYs initially, so the percentage change is less.  
The biggest impact on the ICER was for TA534, where including a utility increment of 0.1 for 
all patients on treatment decreased the ICER by £9,498 (33%). In other appraisals where 
caregiver disutilities were included as a function of patient health states, the impact on the 
ICER was less, with decreases of up to £2,900 (10%).  
 
Committee discussion  
In 11 of the 16 appraisals that included carer HRQL in cost-utility analyses, the committee felt 
that carer HRQL should be included in the base-case cost-effectiveness evidence. In the 
Alzheimer's disease appraisal, the committee used the assessment group’s model in decision-
making, which excluded carer HRQL in the base case, but noted the impact of including carer 
HRQL[10]. In the ADA-SCID and XLH appraisals, the committee felt that the scenarios did 
not fully capture HRQL benefits to carers, and so stated that they would consider carer HRQL 
qualitatively[20, 25]. In the atopic dermatitis appraisal, the committee considered that there 
may be an impact on carer HRQL, but that there was no robust evidence to support this[23]. In 
the myelofibrosis appraisal, the committee concluded that carer HRQL should not be included 
in the estimation of the ICER because the results were not robust; they did not consider that 
the carer burden from myelofibrosis was more profound than that of other severe illnesses; and 
the analysis did not account for the opportunity cost of carer’s burden (that is, the carer burden 





We found that appraisals that included carer HRQL covered a range of clinical areas. While 
there were a high number in multiple sclerosis representing all published multiple sclerosis 
appraisals, the appraisals in Alzheimer's disease, atopic dermatitis, myelofibrosis and all four 
HSTs were each the only published appraisal in that disease area. TA373 which included carer 
HRQL in the cost-utility analysis is one of two published appraisals in juvenile idiopathic 
arthritis, but the committee did discuss the impact of carer HRQL on the ICER in the other 
(TA238).  
Whether carer HRQL is included in economic evaluation may be a function of data availability, 
but we note that Wittenberg et al’s 2019 systematic literature review of family and carer HRQL 
identified carer utilities/disutilities in disease areas other than these appraisals[50]. However, 
the inclusion of carer HRQL in economic evaluations does not appear to be routine even in 
disease areas with substantial data – Wittenberg et al (2019) found 15 (of 80) studies reported 
carer HRQL in Alzheimer's disease, but Lin et al (2019) found that only nine of 63 published 
economic evaluations in Alzheimer's disease or dementia included carer HRQL[51]. 
Although TA386 is the only NICE appraisal in myelofibrosis (a type of blood cancer), none of 
the many other NICE appraisals in cancer included carer HRQL. This is consistent with a 2015 
systematic review across four disease areas which found no economic evaluations in metastatic 
colorectal cancer included either carer HRQL or carer costs, compared to 64% in Alzheimer's 
disease, 13% in Parkinson’s disease and 14% in rheumatoid arthritis. However, in Wittenberg 
et al’s 2019, cancer was the second most commonly reported disease area, with six of 80 
studies[50].  
A substantial proportion of appraisals that considered carer HRQL (either in cost-utility 
analyses or in discussion) included paediatric populations. Wittenberg et al (2019) found less 
data was available for caregivers and family members of ill children than ill adults[50]. 
However, in a separate piece of work we identified 31 TAs which included children in their 
populations[52], so it is clearly not the case that appraisals of interventions in children routinely 
consider carer HRQL. Indeed, Lavelle found that only 15 of 142 identified paediatric economic 
evaluations considered carer HRQL[53].  
How carer HRQL was included in cost-utility analysis 
Methods were largely similar between appraisals, with some notable exceptions. Modelling 
carer HRQL as a function of patients’ health status appears consistent with the data sources in 
most cases, whereas assuming that treatment itself increases a carer’s HRQL without linking 
this to a change in the patient’s health appears to be a simplistic assumption not underpinned 
by evidence in the cases where this was done. Only one appraisal explicitly considered the 
impact of the patient’s death on carer’s HRQL[25], but the data to support this are not well-
reported[30]. The company submissions and assessment group reports did not always clearly 
describe how HRQL was included or how data was used – greater transparency in reporting 
would be beneficial in future cost-utility analyses.  
The number of carers included also appears to be important. In almost all cases, the number of 
carers was assumed to be one. Consideration should be given to the number of carers likely to 
be affected, and how the evidence on the size of carer HRQL should be applied to them. For 
example, Kuhlthau et al (2010) report the effect of having a child with activity limitation on 
HRQL of parents [28] – where children have more than one parent, multiple carer impacts 
could be included. In the two appraisals where this source was used, it was only applied to one 
carer. Canaway et al (2019) found that the impact of care at the end of life impacted a median 
of eight individuals, and suggested that economists should prioritise including the three closest 
individuals[54]. This is much higher than was usually included in NICE appraisals. This raises 
the question as to whether economic evaluations should include carer HRQL effects from 
caring about the individual or only caring for the individual[2]. 
Source of carer HRQL data 
In many cases, there are serious concerns relating to the measurement of carer HRQL, the 
geographic origin and valuation of the source data and the comparison used to derive 
disutilities. We note similar concerns regarding patient HRQL:  a 2011 review found only 56% 
of company submission and assessment group reports contained utility data that conformed to 
the NICE Reference Case[55]. 
The utilities from Neumann et al (2000) used the HUI, whereas NICE specifies that it prefers 
the EQ-5D. HTA bodies should consider whether utility measures for carers should be the same 
as those for patients, or whether different measures better capture the impact on carers[56-60]. 
In terms of data availability, Wittenberg et al (2019) found that the EQ-5D was the most 
common instrument used to measure carer utility (used in 69% of cases)[50].  
Two studies (Neumann et al (2000) and Kuhlthau et al (2010)) were from the US rather than 
the UK, and one study included a mix of countries (Landfeldt (2014)).  Differences in formal 
care provided in the different jurisdictions may impact carer effects. Furthermore, Neumann et 
al (2000) and Kuhlthau et al (2010) use the US value set for EQ-5D and Landfelft (2014) do 
not report which they used, whereas NICE states that the UK value set should be used [6].  
Comparing carer utilities to full-health (utility of 1), as in the appraisals that used the Neumann 
et al (2000) study, does not account for comorbidities in the general population. The use of 
age-adjusted utilities or comparison to general population utility (as in the Landfeldt (2014) 
study) partly addresses this, but limitations remain. More robust estimates of carer disutility 
would result from comparison to a control group (as in Acaster et al (2010) and Kuhlthau et al 
(2010)) or longitudinal studies reporting carer HRQL over time (effectively using carers of 
patients with different health status as the control group). Using longitudinal data of carer’s 
utility would have further benefits, as other evidence has found that carer’s health differs from 
that of non-carers, at least partly because of differences in the populations who become or do 
not become carers[61]. Assuming that carers’ HRQL becomes equivalent to that of non-carers 
if the patient becomes cured ignores these differences between the populations. Similarly, it is 
feasible that people who become carers of people with more severe disease differ from people 
who become carers of people with less severe disease, so assuming that a carer’s HRQL 
improves/worsens as the health of the person they care for improves/worsens is not necessarily 
appropriate. To understand how carer HRQL changes over time (as modelled in cost-utility 
analyses) would require longitudinal studies. 
Impact on incremental QALYs and ICERs 
Including carer HRQL consistently increased incremental QALYs and so interventions 
appeared more cost-effective where carer HRQL was included. Other studies found similar 
results: including carer health outcomes/costs led to less favourable cost-effectiveness results 
in pairwise ICER comparisons for only two of 43 paediatric studies[53] and two of 33 
Alzheimer's disease/dementia studies [51]. 
Committee discussion 
In the cases where the committee did not consider that carer HRQL should be considered in 
decision-making, this was due to a lack of evidence or concern about displacing the carer 
burden currently relieved by other funded interventions. The routine inclusion of carer HRQL 
in economic evaluation would allow for consistency in decision-making, as discussed by 
Brouwer (2019)[5] and McCabe (2019)[62]. This would require evidence on carer HRQL 
across clinical areas. Wittenberg et al (2019) highlight existing publications which report carer 
HRQL [50], but to provide values across clinical areas requires either new studies (for example, 
measuring carer HRQL along with patient HRQL in clinical studies) or prediction of carer 
HRQL from patient HRQL. While it is possible to predict the number of informal hours 
required from the patient’s EQ-5D score and health condition[63, 64], no evidence currently 
exists to predict carer EQ-5D from patient EQ-5D across health conditions, or to predict carer 
EQ-5D from hours of informal care provided (although attempts have been made, for example 
in Alzheimer's disease[65] and meningitis[66]). 
Strengths and limitations 
Our study is the first to systematically search and review the inclusion of carer HRQL in NICE 
appraisals. It is possible that other NICE appraisals have included carer HRQL in cost-utility 
analysis at some stage, but that this was not discussed in the FAD/FED, and so these appraisals 
may have been missed in our searching. However, our aim was to understand what has been 
done to date, rather than to synthesise evidence, so we do not consider that this has biased the 
findings of our review. Our methodology is sufficient to highlight the current issues and 




The inclusion of carer HRQL in NICE appraisals is relatively uncommon and there does not 
appear to be a systematic consideration for when this is relevant. The source data used to 
provide carer HRQL values has been limited to few studies which do not necessarily conform 
to the NICE Reference Case, may be from other disease areas, and are limited in the 
comparison used to derive carer disutilities. For consistency in decision-making, there is a need 
for better quality evidence for carer HRQL across clinical areas and careful consideration as to 
how this should be included in economic evaluation.  
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